Alimera Sciences, Inc. (ALIM) Social Stream
Alimera Sciences Inc (ALIM) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ALIM.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Price Target Last Issued February 25, 2022
The Trend in the Analyst Price Target
ALIM's average price target has moved down $3.5 over the prior 14 months.
Over the past 46 weeks, ALIM's average upside potential has been 109.28%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ALIM Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
ALIM's average broker recommendation rating improved by 1 over the prior 123 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, Alimera Sciences Inc's number of analysts covering the stock is greater than just about none of of them.
- ALIM has a lower variance in analysts' estimates than just about 100% of all US stocks.
- Alimera Sciences Inc's average analyst price target is greater than 35.18% of Healthcare stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Alimera Sciences Inc's upside potential (average analyst target price relative to current price) is greater than 70.22% of them.
In the Pharmaceutical Products industry, ALDX, ALBO, and AKUS are the three stocks most similar to Alimera Sciences Inc regarding the price target and analyst recommendation information presented here.
Is ALIM a Buy, Hold or Sell? See the POWR Ratings now!